《新股消息》艾美疫苗再遞上市申請 上半年盈轉虧蝕8.6億人幣
艾美疫苗上市申請繼7月遭港交所(00388.HK)退回,近日再遞交上市申請。聯席保薦人維持高盛、中金、中信建投(國際)及麥格理。
據初步招股文件顯示,上半年度錄得約8.63億元人民幣(下同)淨虧損,去年同期賺8.85億元,盈轉虧主要是由於一次性股份報酬開支8.97億元;研發成本由4,620萬元增至1.4億元,以開發23種在研疫苗的豐富管線。
集團目前亦有研究4種採用不同技術的新冠疫苗,以及針對Delta變種病毒的疫苗,惟暫仍處試驗階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.